Enrolling By Invitation PHASE1 INTERVENTIONAL 1-arm NCT05868499

Rollover Study From EXG-US-01

Long Term Follow-up Study in Patients With Telomere Biology Disorders With Bone Marrow Failure Who Completed Study EXG-US-01

Sponsor: Elixirgen Therapeutics, Inc.

Conditions Telomere Biology Disorders With Bone Marrow Failure

Interventions EXG34217

Updated 4 times since 2023 Last updated: Jul 10, 2024 Started: Jan 1, 2024 Primary completion: Jan 30, 2027 Completion: Jan 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Telomere Biology Disorders With Bone Marrow Failure, this trial is ongoing. The trial is conducted by Elixirgen Therapeutics, Inc. and has accumulated 4 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Enrolling By Invitation PHASE1
Aug 2024 — Sep 2024 [monthly]

Enrolling By Invitation PHASE1

Status: Not Yet Recruiting → Enrolling By Invitation
Jul 2024 — Aug 2024 [monthly]

Not Yet Recruiting PHASE1
Jun 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Elixirgen Therapeutics, Inc.

Data source: Elixirgen Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cincinnati, United States